tbuckley/cabot-search huggingface dataset:
THU0071 The role of transforming growth factor b (tgfb) in bone metabolism in rheumatoid arthritis
Authors: S Drynda, G Pap, C Kühne, W Neumann, J Kekow
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> TGFb can be found in high concentrations in bone matrix. It is produced by osteoclasts and osteoblasts and is considered as a local regulator of bone metabolism. TGFb is an important factor in the coupling of bone resorption and formation. TGFb induces synthesis of matrix proteins and inhibits matrix degradation by downregulation of MMPs and may thereby counteract pro-resorptive cytokines such as IL-1, IL-6 and TNFa. The role of the different isoforms of TGFb is not yet fully understood. In rheumatoid arthritis elevated plasma levels of TGFb1 and TGFb2 have been described. <h3>Objectives</h3> It was the aim of this study to determine the role of TGFb for bone metabolism in RA. <h3>Methods</h3> 36 RA patients and 55 patients with osteoarthritis (OA) were included in this study. Total TGFbs in plasma samples and bone extracts were determined after transient acidification applying three isoform specific ELISAs. Bone mineral density was measured by dexa-scan (Hologic QDR 4500W) at the lumbar spine and femoral neck. Diagnosis of osteoporosis and osteopenia, respectively, was defined according to the WHO osteoporosis criteria from 1994. <h3>Results</h3> Plasma concentrations of TGFb1 were significantly elevated in RA patients compared to OA patients (7.31 ± 1.10 ng/ml vs. 4.11 ± 0.35 ng/ml, mean ± SEM, p &lt; 0.05), the other two isoforms did not show differences. Concentrations of TGFbs isolated from bone were strongly associated with each other with a predominance of TGFb1 &gt;TGFb2 &gt;TGFb3. Although the concentrations of TGFb1 in bone were slightly elevated in the RA group compared to the OA group (0.49 ± 0.07 vs. 0.38 ± 0.04 ng/mg bone powder) no significant differences were found. No association was found for TGFb levels in peripheral blood and in the corresponding bone extracts. The highest concentrations of TGFb1 from bone were found in patients with reduced bone mineral density. A strong negative correlation was found between bone TGFb1 levels and T-score values (r = -0.479, p = 0.002). <h3>Conclusion</h3> The finding of elevated TGFb1 concentrations in bone samples from patients with osteoporosis is in contrast to earlier findings, which suggest a protective effect of TGFb against matrix degradation. In this study the highest concentrations of extractable TGFb1 were found in RA patients with high bone loss. Thus it may be possible that more proinflammatory features of TGFb are important in bone metabolism, such as the stimulation of IL-6 as described for primary rat osteoblasts. The quantification of total TGFb in the bone matrix may not sufficiently describe the situation <i>in vivo</i>. Post translational processes like activation of the latent TGFb and its availability determine the biological effects of this regulatory cytokine.
N6-Methyladenosine co-transcriptionally directs the demethylation of histone H3K9me2
Authors: Yuan Li, Linjian Xia, Kaifen Tan, Xidong Ye, Zhixiang Zuo, Minchun Li, Rui Xiao, Zihan Wang, Xiaona Liu, Mingqiang Deng, Jinru Cui, Mengtian Yang, Qizhi Luo, Sun Liu, Xin Cao, Haoran Zhu, Tianqi Liu, Jiaxin Hu, Junfang Shi, Shan Xiao, Laixin Xia
Journal: Nature Genetics (2020)
Joan Patricia Wright
Authors: Andrew Dickson, Sue Dickson, Peter Dickson
Journal: BMJ (2020)

Medicine ran in Joan Patricia Wright’s family, and, like both her parents and sister, she studied at the University of Manchester—one of a mere handful of women in her year to qualify. After initial training in Salford and Manchester, she elected to specialise in paediatric cardiology: a bold decision, given that the discipline was only beginning to emerge in the UK and training was essentially on the job. She eventually became a consultant physician at …
Development and validation of a prediction model for severe respiratory failure in hospitalized patients with SARS-CoV-2 infection: a multicentre cohort study (PREDI-CO study)
Authors: Michele Bartoletti, Maddalena Giannella, Luigia Scudeller, Sara Tedeschi, Matteo Rinaldi, Linda Bussini, Giacomo Fornaro, Renato Pascale, Livia Pancaldi, Zeno Pasquini, Filippo Trapani, Lorenzo Badia, Caterina Campoli, Marina Tadolini, Luciano Attard, Massimo Puoti, Marco Merli, Cristina Mussini, Marianna Menozzi, Marianna Meschiari, Mauro Codeluppi, Francesco Barchiesi, Francesco Cristini, Annalisa Saracino, Alberto Licci, Silvia Rapuano, Tommaso Tonetti, Paolo Gaibani, Vito M. Ranieri, Pierluigi Viale, Luigi Raumer, Luca Guerra, Fabio Tumietto, Alessandra Cascavilla, Eleonora Zamparini, Gabriella Verucchi, Simona Coladonato, Arianna Rubin, Stefano Ianniruberto, Eugenia Francalanci, Francesca Volpato, Giulio Virgili, Nicolò Rossi, Elena Rosselli Del Turco, Viola Guardigni, Giovanni Fasulo, Nicola Dentale, Ciro Fulgaro, Giorgio Legnani, Emanuele Campaci, Cristina Basso, Alberto Zuppiroli, Amalia Sanna Passino, Giulia Tesini, Lucia Angelelli, Adriana Badeanu, Agostino Rossi, Giulia Santangelo, Flovia Dauti, Vidak Koprivika, Nicholas Roncagli, Ioannis Tzimas, Guido Maria Liuzzi, Irid Baxhaku, Letizia Pasinelli, Mattia Neri, Tommaso Zanaboni, Francesco Dell'Omo, Oana Vatamanu, Alice Gori, Idina Zavatta, Stefano Antonini, Chiara Pironi, Elena Piccini, Luca Esposito, Alessandro Zuccotti, Giacomo Urbinati, Agnese Pratelli, Alberto Sarti, Michela Semprini, Enrico Evangelisti, Mara D'Onofrio, Giuseppe Sasdelli, Giacinto Pizzilli, Elisabetta Pierucci, Giada Rossini, Caterina Vocale, Lorenzo Marconi, Maria Cristina Leoni, Elisa Fronti, Giovanni Guaraldi, Davide Bavaro, Paola Laghetti
Journal: Clinical Microbiology and Infection (2020)
Filtration Efficiency of Hospital Face Mask Alternatives Available for Use During the COVID-19 Pandemic
Authors: Emily E. Sickbert-Bennett, James M. Samet, Phillip W. Clapp, Hao Chen, Jon Berntsen, Kirby L. Zeman, Haiyan Tong, David J. Weber, William D. Bennett
Journal: JAMA Internal Medicine (2020)

Procuring respiratory protection for clinicians and other health care workers has become a major challenge of the coronavirus disease 2019 (COVID-19) pandemic and has resulted in nonstandard practices such as the use of expired respirators and various decontamination processes to prolong the useful life of respirators in health care settings. In addition, imported, non-National Institute for Occupational Safety and Health (NIOSH)-approved respirators have been donated or acquired by hospitals as a potential replacement for limited NIOSH-approved N95 respirators.
Pathogen-induced tissue-resident memory T <sub>H</sub> 17 (T <sub>RM</sub> 17) cells amplify autoimmune kidney disease
Authors: Christian F. Krebs, Daniel Reimers, Yu Zhao, Hans-Joachim Paust, Patricia Bartsch, Sarah Nuñez, Mariana V. Rosemblatt, Malte Hellmig, Christoph Kilian, Alina Borchers, Leon U. B. Enk, Michael Zinke, Martina Becker, Joanna Schmid, Stefanie Klinge, Milagros N. Wong, Victor G. Puelles, Constantin Schmidt, Tabea Bertram, Natascha Stumpf, Elion Hoxha, Catherine Meyer-Schwesinger, Maja T. Lindenmeyer, Clemens D. Cohen, Michael Rink, Christian Kurts, Sören Franzenburg, Friedrich Koch-Nolte, Jan-Eric Turner, Jan-Hendrik Riedel, Samuel Huber, Nicola Gagliani, Tobias B. Huber, Thorsten Wiech, Holger Rohde, Maria Rosa Bono, Stefan Bonn, Ulf Panzer, Hans-Willi Mittrücker
Journal: Science Immunology (2020)

Although it is well established that microbial infections predispose to autoimmune diseases, the underlying mechanisms remain poorly understood. After infection, tissue-resident memory T (TRM) cells persist in peripheral organs and provide immune protection against reinfection. However, whether TRM cells participate in responses unrelated to the primary infection, such as autoimmune inflammation, is unknown. By using high-dimensional single-cell analysis, we identified CD4+ TRM cells with a TH17 signature (termed TRM17 cells) in kidneys of patients with ANCA-associated glomerulonephritis. Experimental models demonstrated that renal TRM17 cells were induced by pathogens infecting the kidney, such as Staphylococcus aureus, Candida albicans, and uropathogenic Escherichia coli, and persisted after the clearance of infections. Upon induction of experimental glomerulonephritis, these kidney TRM17 cells rapidly responded to local proinflammatory cytokines by producing IL-17A and thereby exacerbate renal pathology. Thus, our data show that pathogen-induced TRM17 cells have a previously unrecognized function in aggravating autoimmune disease.
Elucidation of disease mechanisms underlying rheumatic immune-related adverse events may lead to novel therapeutic strategies for autoimmune diseases
Authors: Ryu Watanabe, Motomu Hashimoto
Journal: Annals of the Rheumatic Diseases (2020)

We read with great interest the article ‘EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors’ by Kostine et al .1 In this article, the authors performed a systematic literature review and generated the first set of recommendations for the diagnosis and management of rheumatic immune-related adverse events (irAEs) induced by checkpoint inhibitors.1 As the authors noted, the paucity of literature on this issue has led to empirical treatment that is not based on evidence. Their points to consider provide a rationale for the management of rheumatic irAEs, as well as help rheumatologists engage with oncologists, thereby enabling patients with cancer to maintain a better quality of …
Synergistic antibacterial activity of physical-chemical multi-mechanism by TiO2 nanorod arrays for safe biofilm eradication on implant
Authors: Xiangyu Zhang, Guannan Zhang, Maozhou Chai, Xiaohong Yao, Weiyi Chen, Paul K. Chu
Journal: Bioactive Materials (2020)

Treatment of implant-associated infection is becoming more challenging, especially when bacterial biofilms form on the surface of the implants. Developing multi-mechanism antibacterial methods to combat bacterial biofilm infections by the synergistic effects are superior to those based on single modality due to avoiding the adverse effects arising from the latter. In this work, TiO
Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI Biologicals Guidelines
Authors: Ioana Agache, Claudio Rocha, Ana Pereira, Yang Song, Pablo Alonso‐Coello, Ivan Solà, Jessica Beltran, Margarita Posso, Cezmi A. Akdis, Mubeccel Akdis, Knut Brockow, Tomas Chivato, Stefano del Giacco, Thomas Eiwegger, Kilian Eyerich, Ana Giménez‐Arnau, Jan Gutermuth, Emma Guttman‐Yassky, Marcus Maurer, Graham Ogg, Peck Ong, Liam O’Mahony, Jürgen Schwarze, Thomas Werfel, Carlos Canelo‐Aybar, Oscar Palomares, Marek Jutel
Journal: Allergy (2020)

Abstract This systematic review evaluates the efficacy and safety of omalizumab for chronic spontaneous urticaria (CSU). PubMed, Embase, and Cochrane Library were searched for RCTs. Critical and important CSU‐related outcomes were considered. The risk of bias and the certainty of the evidence were assessed using GRADE. Ten RCTs including 1620 subjects aged 12 to 75 years old treated with omalizumab for 16 to 40 weeks were evaluated. Omalizumab 150 mg does not result in clinically meaningful improvement (high certainty) of the urticaria activity score (UAS)7 (mean difference (MD) −5; 95%CI −7.75 to −2.25), and the itch severity score (ISS)7 (MD −2.15; 95% CI −3.2 to −1.1) does not increase (moderate certainty) quality of life (QoL) (Dermatology Life Quality Index (DLQI); MD −2.01; 95%CI −3.22 to −0.81) and decreases (moderate certainty) rescue medication use (MD −1.68; 95%CI −2.95 to −0.4). Omalizumab 300 mg results in clinically meaningful improvements (moderate certainty) of the UAS7 (MD −11.05; 95%CI −12.87 to −9.24), the ISS7 (MD −4.45; 95%CI −5.39 to −3.51), and QoL (high certainty) (DLQI; MD −4.03; 95% CI −5.56 to −2.5) and decreases (moderate certainty) rescue medication use (MD −2.04; 95%CI −3.19 to −0.88) and drug‐related serious AEs (RR 0.77; 95%CI 0.20 to 2.91).
Corrigendum to “Dopamine and serotonin regulate tumor behavior by affecting angiogenesis” [Drug Resist. Updat. 17 (2014) 96–104]
Authors: Marloes A.M. Peters, Annemiek M.E. Walenkamp, Ido P. Kema, Coby Meijer, Elisabeth G.E. de Vries, Sjoukje F. Oosting
Journal: Drug Resistance Updates (2020)
The Unacceptable Pace of Progress in Health Disparities Education in Residency Programs
Authors: Alicia Fernandez
Journal: JAMA Network Open (2020)

Denise M. Dupras, MD, PhD; Mark L. Wieland, MD, MPH; Andrew J. Halvorsen, MS; Maria Maldonado, MD; Lisa L. Willett, MD, MACM; Linda Harris
Structural and mechanical aspects of hypoeutectic Zn–Mg binary alloys for biodegradable vascular stent applications
Authors: W. Pachla, S. Przybysz, A. Jarzębska, M. Bieda, K. Sztwiertnia, M. Kulczyk, J. Skiba
Journal: Bioactive Materials (2020)

The study is concerned with the mechanical properties of Zn and three Zn–Mg double alloys with Mg concentrations: 0.5%, 1.0% and 1.5% in the form of rods with a diameter of 5 mm as potential materials for use in biodegradable medical implants, such as vascular stents. The materials were cast, next conventionally hot extruded at 250 °C and finally, hydrostatically extruded (HE) at ambient temperature. Occasionally HE process was carried at liquid nitrogen temperature or in combination with the ECAP process. After HE, the microstructure of the alloys was made up of fine-grained αZn of mean grain size ~1 μm in a 2-phase coat of 50–200 nm nano-grains of the fine αZn + Mg2Zn11 eutectic. The 3 to 4-fold reduction of grain size as a result of HE allowed an increase in yield strength from 100% to over 200%, elongation to fracture from 100% to thirty fold and hardness over 50% compared to the best literature results for similar alloys. Exceptions accounted for elongation to fracture in case of Zn-0.5 Mg alloy and hardness in case of Zn-1.5 Mg alloy, both of which fell by 20%. For the Zn-0.5 Mg and Zn–1Mg alloys, after immersion tests, no corrosive degradation of plasticity was observed. Achieving these properties was the result of generating large plastic deformations at ambient temperature due to the application of high pressure forming with the cumulative HE method. The results showed that Zn–Mg binary alloys after HE have mechanical and corrosive characteristics, qualifying them for applications in biodegradable implants, including vascular stents.
Examining the landscape of skin of color dermatoses: A cross-sectional study at an urban tertiary care center
Authors: Raveena Khanna, Micah Belzberg, Rayva Khanna, Amy H. Huang, Kyle A. Williams, Justin Choi, Nishadh Sutaria, Michael S. Hong, Youkyung S. Roh, Sewon Kang, Crystal Aguh, Shawn G. Kwatra
Journal: Journal of the American Academy of Dermatology (2020)
Abstract 12800: Lesion Location and Outcome in Patients With Multi-Vessel Disease and Acute Myocardial Infarction-Related Cardiogenic Shock, a Sub-Analysis of the Culprit-Shock Trial
Authors: Marie Hauguel-Moreau, Olivier Barthélémy, Michel Zeitouni, Paul Guedeney, Stéphanie Rouanet, Georges Hage, Pavel Overtchouk, Benjamin Bertin, Delphine Brugier, Nicolas Vignolles, Mathieu Kerneis, Johanne Silvain, Jean-Philippe Collet, Eric Vicaut, Serdar Farhan, Uwe Zeymer, Holger Thiele, Gilles Montalescot
Journal: Circulation (2019)

Background: Left main (LM) and proximal left anterior descending (LAD) are critical culprit lesion locations associated with worse clinical outcome in myocardial infarction without cardiogenic shoc...
Expert Perspective: An Evidence‐Based Approach to Refractory Cutaneous Lupus Erythematosus
Authors: Robert Borucki, Victoria P. Werth
Journal: Arthritis & Rheumatology (2020)

Cutaneous lupus erythematosus (CLE) is a chronic autoimmune disease that can present with a variety of skin manifestations and have a dramatic effect on a patient’s quality of life. Effective treatment options for this disease are limited, and the efficacy of these treatments is often supported by low levels of evidence. This makes the treatment of refractory disease especially challenging, as it is difficult to achieve a consensus on the appropriate progression of treatment beyond first‐ and second‐line treatment options. The treatment of refractory CLE often involves some degree of immunosuppression, which carries some risk for patients and requires a thoughtful approach to the selection of medications. Some treatments that have proven to be effective in systemic disease may not be as effective in cutaneous disease, making it difficult to extrapolate from the available evidence on systemic lupus erythematosus (SLE). Ultimately, the increased use of objective skin measurements in SLE clinical trials is necessary to understand drug efficacy in CLE and develop new treatments for this challenging disease. Here, we provide clinical examples of the challenges involved in treating refractory CLE, examine the evidence currently available for treatment options, and provide an algorithmic approach to the treatment of refractory disease based on this evidence. Novel therapies under development for CLE are also discussed, as they may soon be part of the accepted treatment regimen for refractory CLE.
Author Correction: Temporal dynamics in viral shedding and transmissibility of COVID-19
Authors: Xi He, Eric H. Y. Lau, Peng Wu, Xilong Deng, Jian Wang, Xinxin Hao, Yiu Chung Lau, Jessica Y. Wong, Yujuan Guan, Xinghua Tan, Xiaoneng Mo, Yanqing Chen, Baolin Liao, Weilie Chen, Fengyu Hu, Qing Zhang, Mingqiu Zhong, Yanrong Wu, Lingzhai Zhao, Fuchun Zhang, Benjamin J. Cowling, Fang Li, Gabriel M. Leung
Journal: Nature Medicine (2020)

An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Hematopoietic growth factors for graft failure after bone marrow transplantation: a randomized trial of granulocyte-macrophage colony- stimulating factor (GM-CSF) versus sequential GM-CSF plus granulocyte- CSF
Authors: DJ Weisdorf, CM Verfaillie, SM Davies, AH Filipovich, JE Jr Wagner, JS Miller, J Burroughs, NK Ramsay, JH Kersey, PB McGlave
Journal: Blood (1995)
Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure
Authors: Florence Wong, Salvatore Piano, Virendra Singh, Michele Bartoletti, Rakhi Maiwall, Carlo Alessandria, Javier Fernandez, Elza Cotrim Soares, Dong Joon Kim, Sung Eun Kim, Monica Marino, Julio Vorobioff, Rita de Cassia Ribeiro Barea, Manuela Merli, Laure Elkrief, Victor Vargas, Aleksander Krag, Shivaram Prasad Singh, Laurentius Adrianto Lesmana, Claudio Toledo, Sebastian Marciano, Xavier Verhelst, Nicolas Intagliata, Liane Rabinowich, Luis Colombato, Sang Gyune Kim, Alexander Gerbes, Francois Durand, Juan Pablo Roblero, Tony Bruns, Eileen Laurel Yoon, Marcos Girala, Nikolaos T. Pyrsopoulos, Tae Hun Kim, Sun Young Yim, Adria Juanola, Adrian Gadano, Paolo Angeli, Kalyan Bhamidimarri, Thomas D. Boyer, Carlos Brodersen, Daniela Campion, Paolo Caraceni, Robert A. de Man, Eduardo Fassio, Annette Dam Fialla, Carmine Gambino, Vikas Gautam, Pere Gines, Jae Seok Hwang, Hyoung Su Kim, Jeong Han Kim, Pramod Kumar, Barbara Lattanz, Tae Hee Lee, Cosmas A. Rinaldi Lesmana, Marina Maevskaya, Preetam Nath, Gustavo Navarro, Ji-Won Park, Gisela Pinero, Sophie Restellini, Gustavo Romero, Tiago Sevá -Pereira, Macarena Simón-Talero, Do Seon Song, Ki Tae Suk, Hans Van Vlierberghe, Giacomo Zaccherini
Journal: Journal of Hepatology (2020)
Abstract 10800: Mitochondrial Transplantation Into Cardiomyocytes Leads to Transient Enhanced Bioenergetics
Authors: Paria Ali Pour, M. Cristina Kenney, Arash Kheradvar
Journal: Circulation (2019)

Introduction: Lately there has been much interest in mitochondrial transplantation. However, its bioenergetics consequences are yet unknown. This study aims to examine the bioenergetics consequence...
FcγRIIA expression accelerates nephritis and increases platelet activation in systemic lupus erythematosus
Authors: Imene Melki, Isabelle Allaeys, Nicolas Tessandier, Benoit Mailhot, Nathalie Cloutier, Robert A. Campbell, Jesse W. Rowley, David Salem, Anne Zufferey, Audrée Laroche, Tania Lévesque, Natalie Patey, Joyce Rauch, Christian Lood, Arnaud Droit, Steven E. McKenzie, Kellie R. Machlus, Matthew T. Rondina, Steve Lacroix, Paul R. Fortin, Eric Boilard
Journal: Blood (2020)
REPLY:
Authors: Habiba Kamal, Ola Weiland, Soo Aleman
Journal: Hepatology (2020)

We read with interest the letter to the editor by Oynur et al., and we agree that the substantial difference in the interferon (IFN) treatment duration between the two cohorts may have caused differences in some results.(1, 2) As we have pointed out in the discussion section of our study, the median duration of 8.7 months was shorter than the currently recommended duration of at least 48 weeks, according to the guidelines of the European Association for the Study of the Liver.(3) However, this recommendation was not set until recent years in 2017, and the optimal duration of pegylated IFN treatment is still not really established, with recommended minimal duration ranging from 12 to 18 months across guidelines.(3-5) Because of the substantial side effects and the poor overall virological response rate, Swedish clinicians previously tended to end IFN treatment in patients with poor on-treatment virological response at week 24. Stopping the treatment at this stage is not currently recommended in patients tolerating the treatment well because the negative predictive value is not very strong at this time point and late virological responses may occur.(3) We acknowledge the potential benefit of longer duration of IFN-based therapy, with possible prolongation of treatment time in a group of patients with chronic delta hepatitis who show favorable responses during ongoing treatment.(1) Patients who did not or could not receive IFN treatment represent a real-life challenge. In the group of hepatitis D virus (HDV) RNA positive patients with no treatment, 51/95 (53.6%) had contraindications for IFN therapy. Many untreated patients had mild liver disease with a baseline-event anticipation score of A (59.7%), and alanine aminotransferase level was normal in 61.5% of the patients. The shortage of highly effective HDV therapies highlights the urgent need for new therapies, not only considering the many nonresponders to IFN therapy but also for the number of viremic patients who are not eligible/tolerant to IFN treatment.
IL-10 Receptor Deficiency Aggravates Exhaustion of CD8+ T-Cells and Impedes Their Control of Chronic Lymphocytic Leukemia
Authors: Bola S Hanna, Philipp M Röβner, Murat Iskar, Norman Mack, Verena Kalter, Manfred Schmidt, Marc Zapatka, Markus Feuerer, Richard Gabriel, Peter Lichter, Martina Seiffert
Journal: Blood (2017)
Financial Stability as a Goal of Payment Reform—A Lesson From COVID-19
Authors: Suhas Gondi, Dave A. Chokshi
Journal: JAMA (2020)

Amol S. Navathe, MD, PhD; Ezekiel J. Emanuel, MD, PhD; Amelia Bond, PhD; Kristin Linn, PhD; Kristen Caldarella, MHA; Andrea Troxel, PhD; Jingsan Zhu, MS, MBA; Lin Yang, MS; Shireen E. Matloubieh, MPH; Elizabeth Drye, MD, SM; Susannah Bernheim, MD, MHS; Emily Oshima Lee, MA; Mark Mugiishi, MD; Kimberly Takata Endo, MPH; Justin Yoshimoto, MS; Isaac Yuen, BBA; Sheryl Okamura, MPH; Michael Stollar, MA; Jeffrey Tom, MD, MS; Michael Gold, ScD; Kevin G. Volpp, MD, PhD
Abstract 9667: Sonothrombolysis Improves Myocardial Dynamics and Microvascular Obstruction Preventing Left Ventricular Remodeling in Patients With ST Elevation Myocardial Infarction
Authors: Miguel O Aguiar, Jeane Tsutsui, Bruno G Tavares, Bernardo B. C. Lopes, Jose Nicolau, Hsu Po Chiang, Thomas Porter, Bruno Carter C. Borges, Alexandre Soeiro, Múcio T. OliveiraJr., Carlos Rochitte, José A. F Ramires, Roberto Kalil, Wilson Mathias
Journal: Circulation (2019)

Introduction: It has recently been demonstrated that high energy diagnostic transthoracic ultrasound and intravenous microbubbles dissolve thrombi (sonothrombolysis) and increase angiographic recan...